US5430136A
(en)
*
|
1984-10-16 |
1995-07-04 |
Chiron Corporation |
Oligonucleotides having selectably cleavable and/or abasic sites
|
US6335434B1
(en)
|
1998-06-16 |
2002-01-01 |
Isis Pharmaceuticals, Inc., |
Nucleosidic and non-nucleosidic folate conjugates
|
US8153602B1
(en)
|
1991-11-19 |
2012-04-10 |
Isis Pharmaceuticals, Inc. |
Composition and methods for the pulmonary delivery of nucleic acids
|
FR2692265B1
(fr)
|
1992-05-25 |
1996-11-08 |
Centre Nat Rech Scient |
Composes biologiquement actifs de type phosphotriesters.
|
US6020482A
(en)
*
|
1992-05-25 |
2000-02-01 |
Gosselin; Gilles |
Phosphotriester type biologically active compounds
|
US5770725A
(en)
*
|
1992-05-25 |
1998-06-23 |
Gosselin; Gilles |
Phosphotriester type biologically active compounds
|
US5849905A
(en)
*
|
1994-11-23 |
1998-12-15 |
Centre National De La Recherche Scientifique |
Biologically active phosphotriester-type nucleosides and methods for preparing same
|
US5795714A
(en)
*
|
1992-11-06 |
1998-08-18 |
Trustees Of Boston University |
Method for replicating an array of nucleic acid probes
|
US6436635B1
(en)
*
|
1992-11-06 |
2002-08-20 |
Boston University |
Solid phase sequencing of double-stranded nucleic acids
|
US6194144B1
(en)
|
1993-01-07 |
2001-02-27 |
Sequenom, Inc. |
DNA sequencing by mass spectrometry
|
US5605798A
(en)
*
|
1993-01-07 |
1997-02-25 |
Sequenom, Inc. |
DNA diagnostic based on mass spectrometry
|
US5955591A
(en)
*
|
1993-05-12 |
1999-09-21 |
Imbach; Jean-Louis |
Phosphotriester oligonucleotides, amidites and method of preparation
|
CA2170869C
(en)
|
1993-09-03 |
1999-09-14 |
Phillip Dan Cook |
Amine-derivatized nucleosides and oligonucleosides
|
US5986076A
(en)
*
|
1994-05-11 |
1999-11-16 |
Trustees Of Boston University |
Photocleavable agents and conjugates for the detection and isolation of biomolecules
|
US5597909A
(en)
*
|
1994-08-25 |
1997-01-28 |
Chiron Corporation |
Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
|
US5580731A
(en)
*
|
1994-08-25 |
1996-12-03 |
Chiron Corporation |
N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
|
US6428955B1
(en)
|
1995-03-17 |
2002-08-06 |
Sequenom, Inc. |
DNA diagnostics based on mass spectrometry
|
US20060063193A1
(en)
*
|
1995-04-11 |
2006-03-23 |
Dong-Jing Fu |
Solid phase sequencing of double-stranded nucleic acids
|
US7803529B1
(en)
*
|
1995-04-11 |
2010-09-28 |
Sequenom, Inc. |
Solid phase sequencing of biopolymers
|
US5830655A
(en)
|
1995-05-22 |
1998-11-03 |
Sri International |
Oligonucleotide sizing using cleavable primers
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US5856464A
(en)
*
|
1995-06-07 |
1999-01-05 |
Lajolla Pharmaceutical Company |
Selective capping solution phase oligonucleotide synthesis
|
US5998580A
(en)
*
|
1995-10-13 |
1999-12-07 |
Fay; Frederick F. |
Photosensitive caged macromolecules
|
WO1997014812A2
(en)
*
|
1995-10-16 |
1997-04-24 |
Chiron Corporation |
Method of screening for factors that modulate gene expression
|
US6147205A
(en)
*
|
1995-12-15 |
2000-11-14 |
Affymetrix, Inc. |
Photocleavable protecting groups and methods for their use
|
US20110028350A1
(en)
*
|
1995-12-15 |
2011-02-03 |
Affymetrix, Inc. |
Photocleavable protecting groups
|
US6022963A
(en)
*
|
1995-12-15 |
2000-02-08 |
Affymetrix, Inc. |
Synthesis of oligonucleotide arrays using photocleavable protecting groups
|
US6312893B1
(en)
|
1996-01-23 |
2001-11-06 |
Qiagen Genomics, Inc. |
Methods and compositions for determining the sequence of nucleic acid molecules
|
US6027890A
(en)
|
1996-01-23 |
2000-02-22 |
Rapigene, Inc. |
Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
|
US6613508B1
(en)
|
1996-01-23 |
2003-09-02 |
Qiagen Genomics, Inc. |
Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20040266706A1
(en)
*
|
2002-11-05 |
2004-12-30 |
Muthiah Manoharan |
Cross-linked oligomeric compounds and their use in gene modulation
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
AU2980297A
(en)
*
|
1996-06-10 |
1998-01-07 |
Laboratory Of Molecular Biophotonics |
Photocleavable cyclic oligonucleotide
|
US5853990A
(en)
|
1996-07-26 |
1998-12-29 |
Edward E. Winger |
Real time homogeneous nucleotide assay
|
AU735416B2
(en)
*
|
1996-11-06 |
2001-07-05 |
Sequenom, Inc. |
Dna diagnostics based on mass spectrometry
|
US6140053A
(en)
*
|
1996-11-06 |
2000-10-31 |
Sequenom, Inc. |
DNA sequencing by mass spectrometry via exonuclease degradation
|
US6133436A
(en)
*
|
1996-11-06 |
2000-10-17 |
Sequenom, Inc. |
Beads bound to a solid support and to nucleic acids
|
EP1460083B1
(de)
|
1996-11-06 |
2006-01-18 |
Sequenom, Inc. |
Verfahren zur Analyse und Vorrichtung
|
AU5794498A
(en)
*
|
1996-12-10 |
1998-07-03 |
Genetrace Systems, Inc. |
Releasable nonvolatile mass-label molecules
|
US6127533A
(en)
*
|
1997-02-14 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
2'-O-aminooxy-modified oligonucleotides
|
US6172209B1
(en)
|
1997-02-14 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Aminooxy-modified oligonucleotides and methods for making same
|
US6576752B1
(en)
|
1997-02-14 |
2003-06-10 |
Isis Pharmaceuticals, Inc. |
Aminooxy functionalized oligomers
|
CA2294988C
(en)
|
1997-07-01 |
2015-11-24 |
Isis Pharmaceuticals Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
US6365731B1
(en)
|
1997-08-06 |
2002-04-02 |
Ambion, Inc. |
Stripping nucleic acids with iodine and sodium thiosulfate
|
AU8687098A
(en)
*
|
1997-08-05 |
1999-03-01 |
Ambion, Inc. |
Methods and compositions for stripping nucleic acids
|
US6268131B1
(en)
|
1997-12-15 |
2001-07-31 |
Sequenom, Inc. |
Mass spectrometric methods for sequencing nucleic acids
|
US20040186071A1
(en)
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US6723564B2
(en)
|
1998-05-07 |
2004-04-20 |
Sequenom, Inc. |
IR MALDI mass spectrometry of nucleic acids using liquid matrices
|
US6841539B1
(en)
|
1998-05-21 |
2005-01-11 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for topical delivery of oligonucleotides
|
WO1999060012A1
(en)
*
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
JP2002525288A
(ja)
*
|
1998-08-27 |
2002-08-13 |
バイエル コーポレイション |
2重末端選択を用いるオリゴマーの精製
|
US6225293B1
(en)
|
1998-09-02 |
2001-05-01 |
Isis Pharmaceuticals, Inc. |
Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6300320B1
(en)
|
1999-01-05 |
2001-10-09 |
Isis Pharmaceuticals, Inc. |
Modulation of c-jun using inhibitors of protein kinase C
|
US6127124A
(en)
*
|
1999-01-20 |
2000-10-03 |
Isis Pharmaceuticals, Inc. |
Fluorescence based nuclease assay
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US20060275782A1
(en)
|
1999-04-20 |
2006-12-07 |
Illumina, Inc. |
Detection of nucleic acid reactions on bead arrays
|
US20030207295A1
(en)
*
|
1999-04-20 |
2003-11-06 |
Kevin Gunderson |
Detection of nucleic acid reactions on bead arrays
|
ATE553219T1
(de)
|
1999-04-20 |
2012-04-15 |
Illumina Inc |
Erkennung von nukleinsäurereaktionen auf bead- arrays
|
CA2371843A1
(en)
*
|
1999-05-07 |
2000-11-16 |
Yale University |
Multiple tag analysis
|
US8481268B2
(en)
|
1999-05-21 |
2013-07-09 |
Illumina, Inc. |
Use of microfluidic systems in the detection of target analytes using microsphere arrays
|
US8080380B2
(en)
|
1999-05-21 |
2011-12-20 |
Illumina, Inc. |
Use of microfluidic systems in the detection of target analytes using microsphere arrays
|
US6656730B1
(en)
|
1999-06-15 |
2003-12-02 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides conjugated to protein-binding drugs
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
WO2002020150A2
(en)
*
|
2000-09-11 |
2002-03-14 |
Affymetrix, Inc. |
Photocleavable protecting groups
|
US20020164576A1
(en)
*
|
2000-09-22 |
2002-11-07 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
|
US20020115058A1
(en)
*
|
2000-09-22 |
2002-08-22 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
|
US20030044803A1
(en)
*
|
2000-09-22 |
2003-03-06 |
Pedersen Finn Skou |
Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
|
EP2336166A1
(de)
|
2000-10-12 |
2011-06-22 |
University Of Rochester |
Zusammensetzungen die die Proliferation von Krebszellen hemmen
|
US7645441B2
(en)
*
|
2000-12-22 |
2010-01-12 |
Sagres Discovery Inc. |
Compositions and methods in cancer associated with altered expression of PRLR
|
US20030165878A1
(en)
*
|
2000-12-22 |
2003-09-04 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of MCM3AP
|
US20030087252A1
(en)
*
|
2000-12-22 |
2003-05-08 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of PRDM11
|
US20030099963A1
(en)
*
|
2000-12-22 |
2003-05-29 |
Morris David W. |
Novel compositions and methods in cancer associated with altered expression of TBX21
|
US7892730B2
(en)
|
2000-12-22 |
2011-02-22 |
Sagres Discovery, Inc. |
Compositions and methods for cancer
|
US7820447B2
(en)
|
2000-12-22 |
2010-10-26 |
Sagres Discovery Inc. |
Compositions and methods for cancer
|
US7700274B2
(en)
*
|
2000-12-22 |
2010-04-20 |
Sagres Discovery, Inc. |
Compositions and methods in cancer associated with altered expression of KCNJ9
|
US20030232334A1
(en)
*
|
2000-12-22 |
2003-12-18 |
Morris David W. |
Novel compositions and methods for cancer
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
US20030092157A1
(en)
*
|
2001-03-16 |
2003-05-15 |
Hayden Michael R. |
Compositions, screening systems and methods for modulating HDL cholesterol and triglyceride levels
|
US20030191073A1
(en)
|
2001-11-07 |
2003-10-09 |
Challita-Eid Pia M. |
Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
|
EP1390383B1
(de)
|
2001-05-11 |
2012-02-29 |
Isis Pharmaceuticals, Inc. |
Antisense-permeationsverstärker
|
US20050003356A1
(en)
*
|
2001-05-25 |
2005-01-06 |
Hayden Michael R. |
Diagnostic methods for cardiovascular disease, low hdl-cholesterol levels, and high triglyceride levels
|
US7803915B2
(en)
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
EP2000545B1
(de)
|
2001-06-20 |
2011-08-31 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Lungentumoren
|
WO2003000707A2
(en)
|
2001-06-21 |
2003-01-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
DE10142643A1
(de)
*
|
2001-08-31 |
2003-04-24 |
Clondiag Chip Tech Gmbh |
Detektion von Wechselwirkungen auf Sonden-Arrays
|
US20050147984A1
(en)
*
|
2001-08-31 |
2005-07-07 |
Clondiag Chip Technologies Gmbh |
Interaction detection on several probe arrays
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US20070098728A1
(en)
*
|
2001-09-24 |
2007-05-03 |
Pedersen Finn S |
Novel compositions and methods in cancer
|
AU2002334895B2
(en)
|
2001-10-09 |
2006-10-19 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
DE10150121B4
(de)
*
|
2001-10-11 |
2005-12-01 |
Bernhard-Nocht-Institut für Tropenmedizin |
Echtzeitdetektion von DNA-Amplifikationsprodukten
|
US20040166490A1
(en)
*
|
2002-12-17 |
2004-08-26 |
Morris David W. |
Novel therapeutic targets in cancer
|
US20040126762A1
(en)
*
|
2002-12-17 |
2004-07-01 |
Morris David W. |
Novel compositions and methods in cancer
|
US20040197778A1
(en)
*
|
2002-12-26 |
2004-10-07 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
US20060040262A1
(en)
*
|
2002-12-27 |
2006-02-23 |
Morris David W |
Novel compositions and methods in cancer
|
US20040180344A1
(en)
*
|
2003-03-14 |
2004-09-16 |
Morris David W. |
Novel therapeutic targets in cancer
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
KR100623128B1
(ko)
|
2002-01-02 |
2006-09-14 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
DE10201463B4
(de)
|
2002-01-16 |
2005-07-21 |
Clondiag Chip Technologies Gmbh |
Reaktionsgefäß zur Durchführung von Array-Verfahren
|
US8030000B2
(en)
|
2002-02-21 |
2011-10-04 |
Alere San Diego, Inc. |
Recombinase polymerase amplification
|
DK1499738T3
(da)
|
2002-02-21 |
2008-11-17 |
Asm Scient Inc |
Recombinase-polymerease-amplifikation
|
US7399590B2
(en)
|
2002-02-21 |
2008-07-15 |
Asm Scientific, Inc. |
Recombinase polymerase amplification
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
EP2093233A1
(de)
|
2002-03-21 |
2009-08-26 |
Sagres Discovery, Inc. |
Neue Zusammensetzungen und Verfahren bei Krebs
|
MXPA04010092A
(es)
|
2002-04-16 |
2004-12-13 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
US20040092470A1
(en)
*
|
2002-06-18 |
2004-05-13 |
Leonard Sherry A. |
Dry powder oligonucleotide formualtion, preparation and its uses
|
US20040019000A1
(en)
*
|
2002-07-19 |
2004-01-29 |
Muthiah Manoharan |
Polyalkyleneamine-containing oligomers
|
EP1575992A4
(de)
|
2002-08-05 |
2007-02-21 |
Univ Rochester |
Chimäre proteine aus proteintransduzierender domäne/deaminase, verwandte verbindungen und deren verwendungen
|
WO2004016733A2
(en)
|
2002-08-16 |
2004-02-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
|
US6878805B2
(en)
*
|
2002-08-16 |
2005-04-12 |
Isis Pharmaceuticals, Inc. |
Peptide-conjugated oligomeric compounds
|
EP1537208A1
(de)
|
2002-09-13 |
2005-06-08 |
Replicor, Inc. |
Nicht-sequenzkomplementäre antivirale oligonukleotide
|
EP1549767A4
(de)
|
2002-09-26 |
2006-06-07 |
Amgen Inc |
Modulation der expression von forkhead-box o1a
|
EP1560839A4
(de)
|
2002-11-05 |
2008-04-23 |
Isis Pharmaceuticals Inc |
Chimäre oligomere verbindungen und derenverwendung in der genmodulation
|
US9150605B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
WO2004041889A2
(en)
|
2002-11-05 |
2004-05-21 |
Isis Pharmaceuticals, Inc. |
Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
WO2004044136A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
|
US9150606B2
(en)
|
2002-11-05 |
2015-10-06 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
JP4986109B2
(ja)
|
2002-11-13 |
2012-07-25 |
ジェンザイム・コーポレーション |
アポリポタンパク質b発現のアンチセンス調節
|
PT2336318E
(pt)
|
2002-11-13 |
2013-06-12 |
Genzyme Corp |
Modulação anti-sentido da expressão de apolipoproteína b
|
JP4915980B2
(ja)
|
2002-11-15 |
2012-04-11 |
エムユーエスシー ファウンデーション フォー リサーチ デベロップメント |
補体レセプター2標的化補体調節因子
|
JP4555089B2
(ja)
|
2002-11-15 |
2010-09-29 |
モーフオテク・インコーポレーテツド |
invitro免疫感作により創製されたハイブリドーマからの抗体の高生産量の生成方法
|
ATE542423T1
(de)
|
2002-11-21 |
2012-02-15 |
Univ Utah Res Found |
Purinerge geruchsmodulation
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US7625872B2
(en)
*
|
2002-12-23 |
2009-12-01 |
Dynavax Technologies Corporation |
Branched immunomodulatory compounds and methods of using the same
|
CA2860151A1
(en)
|
2003-02-10 |
2004-08-26 |
Agensys, Inc. |
Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
|
WO2004072284A1
(en)
|
2003-02-11 |
2004-08-26 |
Antisense Therapeutics Ltd |
Modulation of insulin like growth factor i receptor expression
|
US20070218071A1
(en)
*
|
2003-09-15 |
2007-09-20 |
Morris David W |
Novel therapeutic targets in cancer
|
WO2004074321A2
(en)
|
2003-02-14 |
2004-09-02 |
Sagres Discovery, Inc. |
Therapeutic gpcr targets in cancer
|
US20040170982A1
(en)
*
|
2003-02-14 |
2004-09-02 |
Morris David W. |
Novel therapeutic targets in cancer
|
US7767387B2
(en)
*
|
2003-06-13 |
2010-08-03 |
Sagres Discovery, Inc. |
Therapeutic targets in cancer
|
US6943768B2
(en)
|
2003-02-21 |
2005-09-13 |
Xtellus Inc. |
Thermal control system for liquid crystal cell
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
CN101090729B
(zh)
|
2003-05-30 |
2014-07-23 |
艾更斯司股份有限公司 |
前列腺干细胞抗原(psca)变体及其序列
|
CA2540692C
(en)
|
2003-06-02 |
2013-05-28 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide synthesis with alternative solvents
|
BRPI0410886A
(pt)
|
2003-06-03 |
2006-07-04 |
Isis Pharmaceuticals Inc |
composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único
|
DK3604537T3
(da)
|
2003-06-13 |
2022-02-28 |
Alnylam Europe Ag |
Dobbeltstrenget ribonukleinsyre med forøget effektivitet i en organisme
|
US20040259100A1
(en)
|
2003-06-20 |
2004-12-23 |
Illumina, Inc. |
Methods and compositions for whole genome amplification and genotyping
|
US7790691B2
(en)
*
|
2003-06-20 |
2010-09-07 |
Isis Pharmaceuticals, Inc. |
Double stranded compositions comprising a 3′-endo modified strand for use in gene modulation
|
US7683036B2
(en)
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US7354706B2
(en)
*
|
2003-09-09 |
2008-04-08 |
The Regents Of The University Of Colorado, A Body Corporate |
Use of photopolymerization for amplification and detection of a molecular recognition event
|
US20050053981A1
(en)
|
2003-09-09 |
2005-03-10 |
Swayze Eric E. |
Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
|
US20090163375A1
(en)
|
2003-09-09 |
2009-06-25 |
Bowman Christopher N |
Use of Photopolymerization for Amplification and Detection of a Molecular Recognition Event
|
EP1668130A2
(de)
|
2003-09-18 |
2006-06-14 |
Isis Pharmaceuticals, Inc. |
Modulation der eif4e-expression
|
JP5379347B2
(ja)
|
2003-09-18 |
2013-12-25 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
4’−チオヌクレオシドおよびオリゴマー化合物
|
US20070281896A1
(en)
*
|
2003-09-30 |
2007-12-06 |
Morris David W |
Novel compositions and methods in cancer
|
US7662929B2
(en)
|
2003-10-10 |
2010-02-16 |
Alchemia Oncology Pty Limited |
Antibody that specifically binds hyaluronan synthase
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
US20050136417A1
(en)
*
|
2003-12-19 |
2005-06-23 |
Affymetrix, Inc. |
Amplification of nucleic acids
|
US20050136414A1
(en)
*
|
2003-12-23 |
2005-06-23 |
Kevin Gunderson |
Methods and compositions for making locus-specific arrays
|
US20050164271A1
(en)
|
2004-01-20 |
2005-07-28 |
Sanjay Bhanot |
Modulation of glucocorticoid receptor expression
|
US7468431B2
(en)
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US8778900B2
(en)
|
2004-01-22 |
2014-07-15 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP1 expression
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
US20050244869A1
(en)
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
WO2005097817A2
(en)
|
2004-04-05 |
2005-10-20 |
Alnylam Pharmaceuticals, Inc. |
Process and reagents for oligonucleotide synthesis and purification
|
EP1750776A2
(de)
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonukleotide mit c5-modifiziertem pyrimidin
|
IL179285A
(en)
|
2004-05-14 |
2011-04-28 |
Rosetta Genomics Ltd |
Micrornas and uses thereof
|
EP2322652A1
(de)
|
2004-05-14 |
2011-05-18 |
Rosetta Genomics Ltd |
Mikro-RNAs und deren Verwendung
|
US8039588B2
(en)
|
2004-05-21 |
2011-10-18 |
The Uab Research Foundation |
Variable lymphocyte receptors
|
US7473551B2
(en)
|
2004-05-21 |
2009-01-06 |
Atonomics A/S |
Nano-mechanic microsensors and methods for detecting target analytes
|
AU2005250370B2
(en)
|
2004-05-28 |
2010-04-01 |
Agensys, Inc. |
Antibodies and related molecules that bind to PSCA proteins
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
WO2006023880A2
(en)
*
|
2004-08-23 |
2006-03-02 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for the characterization of oligonucleotides
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
CA2623471C
(en)
|
2004-09-23 |
2018-02-13 |
Arc Pharmaceuticals, Inc. |
Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans
|
US8338093B2
(en)
*
|
2004-12-31 |
2012-12-25 |
Affymetrix, Inc. |
Primer array synthesis and validation
|
US7547775B2
(en)
*
|
2004-12-31 |
2009-06-16 |
Affymetrix, Inc. |
Parallel preparation of high fidelity probes in an array format
|
CA2596496A1
(en)
|
2005-02-01 |
2006-08-10 |
Agencourt Bioscience Corp. |
Reagents, methods, and libraries for bead-based sequencing
|
CA2597325A1
(en)
|
2005-03-10 |
2006-09-21 |
Genentech, Inc. |
Methods and compositions for modulating vascular integrity
|
WO2006105488A2
(en)
|
2005-03-31 |
2006-10-05 |
Agensys, Inc. |
Antibodies and related molecules that bind to 161p2f10b proteins
|
WO2006110581A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes
|
EP1865981A2
(de)
|
2005-04-07 |
2007-12-19 |
Chiron Corporation |
Cacna1e in der diagnose und nachweis von sowie als therapeutisches mittel gegen krebs
|
US9505867B2
(en)
|
2005-05-31 |
2016-11-29 |
Ecole Polytechmique Fédérale De Lausanne |
Triblock copolymers for cytoplasmic delivery of gene-based drugs
|
US8252756B2
(en)
|
2005-06-14 |
2012-08-28 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
EP1929049B1
(de)
|
2005-07-25 |
2013-04-10 |
Alere San Diego, Inc. |
Verfahren zur multiplexierung einer rekombinase-polymerase-verstärkung
|
US8080534B2
(en)
|
2005-10-14 |
2011-12-20 |
Phigenix, Inc |
Targeting PAX2 for the treatment of breast cancer
|
CA2625891A1
(en)
|
2005-10-14 |
2007-04-26 |
Carlton D. Donald |
Inhibition of pax2 by defb1 induction as a therapy for cancer
|
US7320965B2
(en)
|
2005-10-28 |
2008-01-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Huntingtin gene
|
WO2007056331A2
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
US7807652B2
(en)
|
2005-11-21 |
2010-10-05 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
CN101437933B
(zh)
|
2005-12-28 |
2013-11-06 |
斯克里普斯研究所 |
作为药物靶标的天然反义和非编码的rna转录物
|
US7718629B2
(en)
|
2006-03-31 |
2010-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 gene
|
EP2013344B1
(de)
|
2006-05-03 |
2012-08-29 |
Baltic Technology Development, Ltd. |
Antisense-agentien mit kombination von mit stark gebundener base modifiziertem oligonukleotid und künstlicher nuklease
|
EP2029782B1
(de)
|
2006-05-04 |
2014-11-26 |
Alere San Diego, Inc. |
Rekombinase-polymerase-verstärkung
|
US7812150B2
(en)
|
2006-05-19 |
2010-10-12 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of Aha and therapeutic uses thereof
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
US20090280188A1
(en)
*
|
2006-06-23 |
2009-11-12 |
Northwestern University |
Asymmetric functionalizated nanoparticles and methods of use
|
AU2007293187A1
(en)
*
|
2006-06-30 |
2008-03-13 |
Rosetta Genomics Ltd |
A method for detecting nucleic acids
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
US8999317B2
(en)
|
2006-11-01 |
2015-04-07 |
University Of Rochester |
Methods and compositions related to the structure and function of APOBEC3G
|
US8481506B2
(en)
*
|
2006-12-05 |
2013-07-09 |
Rosetta Genomics, Ltd. |
Nucleic acids involved in viral infection
|
JP2010512327A
(ja)
|
2006-12-11 |
2010-04-22 |
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション |
病的血管形成および脈管透過性の処置用の組成物および方法
|
KR100827449B1
(ko)
|
2007-02-07 |
2008-05-07 |
삼성전자주식회사 |
광분해성 화합물과 상기 화합물이 커플링된 올리고머프로브 어레이용 기판, 올리고머 프로브 어레이 및 이의제조 방법
|
MX2009008470A
(es)
|
2007-02-09 |
2009-11-26 |
Univ Northwestern |
Particulas para detectar objetivos intracelulares.
|
US20080241140A1
(en)
*
|
2007-02-12 |
2008-10-02 |
Medical College Of Georgia |
Gene amplification of coactivator coaa and uses thereof
|
US7759320B2
(en)
|
2007-03-29 |
2010-07-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the Ebola
|
AU2008259907B2
(en)
|
2007-05-30 |
2014-12-04 |
Northwestern University |
Nucleic acid functionalized nanoparticles for therapeutic applications
|
AU2008296478B9
(en)
|
2007-08-28 |
2015-03-19 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
AU2008296487A1
(en)
|
2007-08-28 |
2009-03-12 |
The Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
US9388457B2
(en)
|
2007-09-14 |
2016-07-12 |
Affymetrix, Inc. |
Locus specific amplification using array probes
|
US8445217B2
(en)
|
2007-09-20 |
2013-05-21 |
Vanderbilt University |
Free solution measurement of molecular interactions by backscattering interferometry
|
US7951785B2
(en)
|
2007-09-21 |
2011-05-31 |
California Institute Of Technology |
NFIA in glial fate determination, glioma therapy and astrocytoma treatment
|
AU2008307482B2
(en)
|
2007-10-02 |
2012-07-12 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-RNA and precursors thereof
|
WO2009045536A2
(en)
*
|
2007-10-05 |
2009-04-09 |
The University Of North Carolina At Chapel Hill |
Receptor targeted oligonucleotides
|
US20090137405A1
(en)
*
|
2007-11-16 |
2009-05-28 |
Christopher Bowman |
Detection of nucleic acid biomarkers using polymerization-based amplification
|
WO2009067243A2
(en)
|
2007-11-20 |
2009-05-28 |
Isis Pharmaceuticals Inc. |
Modulation of cd40 expression
|
EP2848688A1
(de)
|
2007-12-10 |
2015-03-18 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
|
CN105267233B
(zh)
|
2008-03-05 |
2019-07-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
EP2105145A1
(de)
*
|
2008-03-27 |
2009-09-30 |
ETH Zürich |
Verfahren zur muskelspezifischen Abgabe lipidkonjugierter Oligonukleotide
|
EP2274423A2
(de)
*
|
2008-04-04 |
2011-01-19 |
Isis Pharmaceuticals, Inc. |
Bicyclische nukleoside umfassende oligomere verbindungen mit verringerter toxizität
|
JP5788312B2
(ja)
|
2008-04-11 |
2015-09-30 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達
|
US8324366B2
(en)
|
2008-04-29 |
2012-12-04 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for delivering RNAI using lipoproteins
|
NZ591416A
(en)
|
2008-08-25 |
2012-11-30 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
|
EP2690175B1
(de)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
|
US8962580B2
(en)
|
2008-09-23 |
2015-02-24 |
Alnylam Pharmaceuticals, Inc. |
Chemical modifications of monomers and oligonucleotides with cycloaddition
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
EA020312B1
(ru)
|
2008-10-20 |
2014-10-30 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы для ингибирования экспрессии транстиретина
|
WO2010048585A2
(en)
|
2008-10-24 |
2010-04-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
KR20220150995A
(ko)
|
2008-11-10 |
2022-11-11 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
EP2365803B1
(de)
|
2008-11-24 |
2017-11-01 |
Northwestern University |
Polyvalente rna-nanoteilchen-zusammensetzungen
|
WO2010065662A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
ES2629630T3
(es)
|
2008-12-04 |
2017-08-11 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con eritropoyetina (EPO) mediante inhibición del transcrito antisentido natural a EPO
|
MX2011005918A
(es)
|
2008-12-04 |
2011-06-17 |
Opko Curna Llc |
Tratamiento de enfermedades relacionadas con un gen supresor de tumor mediante inhibicion del transcrito antisentido natural para el gen.
|
AU2009324534B2
(en)
|
2008-12-10 |
2015-07-30 |
Alnylam Pharmaceuticals, Inc. |
GNAQ targeted dsRNA compositions and methods for inhibiting expression
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
WO2010091308A2
(en)
|
2009-02-06 |
2010-08-12 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and methods
|
JP6066035B2
(ja)
|
2009-02-12 |
2017-01-25 |
クルナ・インコーポレーテッド |
グリア細胞由来神経栄養因子(gdnf)関連疾病の、gdnfに対する天然アンチセンス転写物の抑制による治療
|
CA2752237C
(en)
|
2009-02-12 |
2020-03-24 |
Opko Curna, Llc |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
EP2399129B1
(de)
|
2009-02-20 |
2015-11-25 |
Michael P. Lisanti |
Verfahren zur diagnose bzw. prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma
|
US9347092B2
(en)
|
2009-02-25 |
2016-05-24 |
Roche Molecular System, Inc. |
Solid support for high-throughput nucleic acid analysis
|
JP5457222B2
(ja)
|
2009-02-25 |
2014-04-02 |
エフ.ホフマン−ラ ロシュ アーゲー |
小型化ハイスループット核酸分析
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
US8975389B2
(en)
|
2009-03-02 |
2015-03-10 |
Alnylam Pharmaceuticals, Inc. |
Nucleic acid chemical modifications
|
ES2845644T3
(es)
|
2009-03-04 |
2021-07-27 |
Curna Inc |
Tratamiento de enfermedades relacionadas con sirtuina1 (SIRT1) mediante inhibición del transcrito del antisentido natural a sirtuina 1
|
EP2406376A1
(de)
|
2009-03-12 |
2012-01-18 |
Alnylam Pharmaceuticals, Inc. |
Lipidformulierte zusammensetzungen und verfahren zur hemmung der expression von eg5- und vegf-genen
|
CA2755409C
(en)
|
2009-03-16 |
2019-04-30 |
Joseph Collard |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
CA2755404C
(en)
|
2009-03-17 |
2020-03-24 |
Joseph Collard |
Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
|
EP3248618A1
(de)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Angeborene immununterdrückung mit ermöglichung der wiederholten verabreichung von langen rna-molekülen
|
NO2424987T3
(de)
|
2009-05-01 |
2018-04-14 |
|
|
CA2761142C
(en)
|
2009-05-06 |
2021-06-08 |
Opko Curna, Llc |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
CN102575251B
(zh)
|
2009-05-18 |
2018-12-04 |
库尔纳公司 |
通过抑制针对重编程因子的天然反义转录物来治疗重编程因子相关的疾病
|
EP2432795B1
(de)
*
|
2009-05-20 |
2015-03-04 |
Alere San Diego, Inc. |
Dna-glycosylase/lyase- und ap-endonukleasesubstrate
|
US8895527B2
(en)
|
2009-05-22 |
2014-11-25 |
Curna, Inc. |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3
|
CA2764683A1
(en)
|
2009-05-28 |
2010-12-02 |
Joseph Collard |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
WO2010141940A1
(en)
|
2009-06-05 |
2010-12-09 |
Alere San Diego, Inc. |
Recombinase polymerase amplification reagents and kits
|
TR201811076T4
(tr)
|
2009-06-10 |
2018-08-27 |
Arbutus Biopharma Corp |
Geliştirilmiş lipit formulasyonu.
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
ES2620960T3
(es)
|
2009-06-16 |
2017-06-30 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con un gen de colágeno mediante la inhibición de un transcrito antisentido natural a un gen de colágeno
|
CN106983768B
(zh)
|
2009-06-17 |
2023-04-07 |
冷泉港实验室 |
用于在对象中调节smn2剪接的组合物和方法
|
JP6073133B2
(ja)
|
2009-06-24 |
2017-02-01 |
クルナ・インコーポレーテッド |
腫瘍壊死因子受容体2(tnfr2)に対する天然アンチセンス転写物の抑制によるtnfr2関連疾患の治療
|
WO2010151674A2
(en)
|
2009-06-26 |
2010-12-29 |
Curna, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
KR101802536B1
(ko)
|
2009-08-05 |
2017-11-28 |
큐알엔에이, 인크. |
인슐린 유전자 (ins)에 대한 자연 안티센스 전사체의 저해에 의한 인슐린 유전자 (ins) 관련된 질환의 치료
|
EP2810643A3
(de)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen aus Lipidformulierung und Verfahren zur Hemmung der Expression eines Gens aus dem Ebola-Virus
|
JP5964232B2
(ja)
|
2009-08-25 |
2016-08-03 |
カッパーアールエヌエー,インコーポレイテッド |
‘iqモチーフ含有gtpアーゼ活性化タンパク質’(iqgap)に対する天然アンチセンス転写産物の阻害によるiqgap関連疾患の治療
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
RU2539772C2
(ru)
|
2009-10-22 |
2015-01-27 |
Дженентек, Инк. |
Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
|
US9376690B2
(en)
|
2009-10-30 |
2016-06-28 |
Northwestern University |
Templated nanoconjugates
|
MX2012006072A
(es)
|
2009-11-30 |
2012-07-23 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores.
|
EP2509636B1
(de)
|
2009-12-07 |
2017-07-19 |
Arbutus Biopharma Corporation |
Zusammensetzungen für nukleinsäurefreisetzung
|
DK2513310T3
(en)
|
2009-12-16 |
2018-02-05 |
Curna Inc |
TREATMENT OF DISEASES CONNECTED WITH MEMBRANE-BONDED TRANSCRIPTION FACTOR Peptidase, site 1 (MBTPS1), BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO MBTPS1
|
CA2784568A1
(en)
|
2009-12-18 |
2011-06-23 |
Martin A. Maier |
Lipid particles for delivery of nucleic acids
|
DK2516648T3
(en)
|
2009-12-23 |
2018-02-12 |
Curna Inc |
TREATMENT OF HEPATOCYTE GROWTH FACTOR (HGF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT AGAINST HGF
|
EP2515947B1
(de)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Behandlung von durch das uncoupling protein 2 (ucp2) bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts für ucp2
|
JP5993744B2
(ja)
|
2009-12-29 |
2016-09-14 |
カッパーアールエヌエー,インコーポレイテッド |
核呼吸因子1(nrf1)に対する天然アンチセンス転写物の阻害による核呼吸因子1関連疾患の治療
|
EP2519634B1
(de)
|
2009-12-29 |
2016-06-01 |
CuRNA, Inc. |
Behandlung von durch das tumorprotein 63 (p63) vermittelten erkrankungen durch das natürliche antisense-transkript für p63
|
EP2521784B1
(de)
|
2010-01-04 |
2017-12-06 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit dem interferonregulierungsfaktor 8 (irf8) mittels hemmung des natürlichen antisense-transkripts gegen irf8
|
EP2521785B1
(de)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
|
ES2664866T3
(es)
|
2010-01-11 |
2018-04-23 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con la globulina fijadora de hormonas sexuales (shbg) mediante inhibición del transcrito antisentido natural a shbg
|
DK2529015T3
(en)
|
2010-01-25 |
2018-02-26 |
Curna Inc |
TREATMENT OF RNASE H1-RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNASE H1
|
WO2011100131A2
(en)
|
2010-01-28 |
2011-08-18 |
Alnylam Pharmacuticals, Inc. |
Monomers and oligonucleotides comprising cycloaddition adduct(s)
|
WO2011094580A2
(en)
|
2010-01-28 |
2011-08-04 |
Alnylam Pharmaceuticals, Inc. |
Chelated copper for use in the preparation of conjugated oligonucleotides
|
US20130028889A1
(en)
|
2010-02-04 |
2013-01-31 |
Ico Therapeutics Inc. |
Dosing regimens for treating and preventing ocular disorders using c-raf antisense
|
CA2790506A1
(en)
|
2010-02-22 |
2011-08-25 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
|
WO2011105901A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 9 (c9) and uses thereof
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
WO2011105900A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
|
WO2011105902A2
(en)
|
2010-02-23 |
2011-09-01 |
Academisch Ziekenhuis Bij De Universiteit Van Amsterdam |
Antagonists of complement component 8-beta (c8-beta) and uses thereof
|
WO2011112516A1
(en)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
|
ES2743600T3
(es)
|
2010-03-12 |
2020-02-20 |
Brigham & Womens Hospital Inc |
Métodos de tratamiento de los trastornos inflamatorios vasculares
|
WO2011123468A1
(en)
|
2010-03-29 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Sirna therapy for transthyretin (ttr) related ocular amyloidosis
|
WO2011123621A2
(en)
|
2010-04-01 |
2011-10-06 |
Alnylam Pharmaceuticals Inc. |
2' and 5' modified monomers and oligonucleotides
|
EP4385568A2
(de)
|
2010-04-06 |
2024-06-19 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der cd274/pd-l1-genexpression
|
TWI644675B
(zh)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
藉由抑制纖維母細胞生長因子21(fgf21)之天然反義轉錄物以治療fgf21相關疾病
|
WO2011133876A2
(en)
*
|
2010-04-22 |
2011-10-27 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising acyclic and abasic nucleosides and analogs
|
US9725479B2
(en)
|
2010-04-22 |
2017-08-08 |
Ionis Pharmaceuticals, Inc. |
5′-end derivatives
|
US20130260460A1
(en)
|
2010-04-22 |
2013-10-03 |
Isis Pharmaceuticals Inc |
Conformationally restricted dinucleotide monomers and oligonucleotides
|
WO2011139699A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
5' modified nucleosides and oligomeric compounds prepared therefrom
|
WO2011139695A2
(en)
|
2010-04-28 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modified 5' diphosphate nucleosides and oligomeric compounds prepared therefrom
|
EP2601204B1
(de)
|
2010-04-28 |
2016-09-07 |
Ionis Pharmaceuticals, Inc. |
Modifizierte nukleoside und daraus hergestellte oligomere verbindungen
|
US20130156845A1
(en)
|
2010-04-29 |
2013-06-20 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
WO2011139917A1
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Modulation of transthyretin expression
|
KR20130101442A
(ko)
|
2010-05-03 |
2013-09-13 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
JP5973996B2
(ja)
|
2010-05-26 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Atoh1に対する天然アンチセンス転写物の阻害による無調ホモログ1(atoh1)関連疾患の治療
|
CA2801066C
(en)
|
2010-06-02 |
2021-02-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods directed to treating liver fibrosis
|
WO2011156713A1
(en)
|
2010-06-11 |
2011-12-15 |
Vanderbilt University |
Multiplexed interferometric detection system and method
|
WO2011163121A1
(en)
|
2010-06-21 |
2011-12-29 |
Alnylam Pharmaceuticals, Inc. |
Multifunctional copolymers for nucleic acid delivery
|
RU2611190C2
(ru)
|
2010-07-14 |
2017-02-21 |
Курна, Инк. |
Лечение заболеваний, связанных с геном dlg, путем ингибирования природного антисмыслового транскрипта гена dlg
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
WO2012016184A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
SG188666A1
(en)
|
2010-09-30 |
2013-05-31 |
Agency Science Tech & Res |
Methods and reagents for detection and treatment of esophageal metaplasia
|
EP2625197B1
(de)
|
2010-10-05 |
2016-06-29 |
Genentech, Inc. |
Smoothened-mutant und verfahren zu seiner anwendung
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
WO2012048113A2
(en)
|
2010-10-07 |
2012-04-12 |
The General Hospital Corporation |
Biomarkers of cancer
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
RU2611195C2
(ru)
|
2010-10-27 |
2017-02-21 |
Курна, Инк. |
Лечение заболеваний, связанных с интерферон- связанным регулятором развития 1 (ifrd1), путем ингибирования природного антисмыслового транскрипта к ifrd1
|
US9339513B2
(en)
|
2010-11-09 |
2016-05-17 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
JP6336755B2
(ja)
|
2010-11-12 |
2018-06-06 |
ザ ジェネラル ホスピタル コーポレイション |
ポリコームに関連する非コードrna
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
US9193973B2
(en)
|
2010-12-10 |
2015-11-24 |
Alynylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (EPO) production
|
EP2648763A4
(de)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
|
DK2663548T3
(en)
|
2011-01-11 |
2017-07-24 |
Alnylam Pharmaceuticals Inc |
PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
|
US9045749B2
(en)
|
2011-01-14 |
2015-06-02 |
The General Hospital Corporation |
Methods targeting miR-128 for regulating cholesterol/lipid metabolism
|
PL2670411T3
(pl)
|
2011-02-02 |
2019-09-30 |
Excaliard Pharmaceuticals, Inc. |
Związki antysensowne ukierunkowane na czynnik wzrostu tkanki łącznej (ctgf) do leczenia bliznowców lub blizn przerostowych
|
EP2678026B1
(de)
|
2011-02-21 |
2016-05-18 |
The University of Zurich |
Ankyrin-g zur verwendung in der behandlung von neurodegenerativer erkrankungen
|
US9562853B2
(en)
|
2011-02-22 |
2017-02-07 |
Vanderbilt University |
Nonaqueous backscattering interferometric methods
|
KR102481317B1
(ko)
|
2011-03-29 |
2022-12-26 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
CN103620036B
(zh)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
|
WO2012177949A2
(en)
|
2011-06-21 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of expression of protein c (proc) genes
|
US9315813B2
(en)
|
2011-06-21 |
2016-04-19 |
Alnylam Pharmaceuticals, Inc |
Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
|
ES2923573T3
(es)
|
2011-06-21 |
2022-09-28 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
EP2739735A2
(de)
|
2011-08-01 |
2014-06-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren zur verbesserung der erfolgsquote von hämatopoetischen stammzellentransplantaten
|
DK2756080T3
(da)
|
2011-09-14 |
2019-05-20 |
Translate Bio Ma Inc |
Multimeriske oligonukleotidforbindelser
|
CN104023749B
(zh)
|
2011-09-14 |
2019-12-17 |
西北大学 |
能穿过血脑屏障的纳米缀合物
|
EP2760477B1
(de)
|
2011-09-27 |
2018-08-08 |
Alnylam Pharmaceuticals, Inc. |
Substituierte di-aliphatic pegylierte lipide
|
CA2851280C
(en)
|
2011-10-11 |
2021-05-18 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
CN103987858A
(zh)
|
2011-11-22 |
2014-08-13 |
英特芒尼公司 |
诊断和治疗特发性肺纤维化的方法
|
US10557136B2
(en)
|
2011-12-12 |
2020-02-11 |
Oncolmmunin Inc. |
In vivo delivery of oligonucleotides
|
KR20140102759A
(ko)
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
WO2013112881A1
(en)
|
2012-01-27 |
2013-08-01 |
Thomas Jefferson University |
Mct protein inhibitor-related prognostic and therapeutic methods
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
EP2833892A4
(de)
|
2012-04-02 |
2016-07-20 |
Moderna Therapeutics Inc |
Modifizierte polynukleotide zur herstellung von in der onkologie nützlichen proteinen und peptiden
|
WO2013151666A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
US20150211005A1
(en)
|
2012-04-20 |
2015-07-30 |
Aptamir Therapeutics, Inc. |
Mirna modulators of thermogenesis
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
US9273949B2
(en)
|
2012-05-11 |
2016-03-01 |
Vanderbilt University |
Backscattering interferometric methods
|
JP2015518714A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
遺伝子発現を調節するための組成物及び方法
|
EA201492123A1
(ru)
|
2012-05-16 |
2015-10-30 |
Рана Терапьютикс, Инк. |
Композиции и способы для модулирования экспрессии семейства генов smn
|
US20150216892A1
(en)
|
2012-08-03 |
2015-08-06 |
Aptamir Therapeutics, Inc. |
Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
JP2016503300A
(ja)
|
2012-11-15 |
2016-02-04 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
抗ApoBアンチセンス複合体化合物
|
JP6144355B2
(ja)
|
2012-11-26 |
2017-06-07 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
化学修飾mRNA
|
JP2016504050A
(ja)
|
2013-01-17 |
2016-02-12 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
|
WO2014118272A1
(en)
|
2013-01-30 |
2014-08-07 |
Santaris Pharma A/S |
Antimir-122 oligonucleotide carbohydrate conjugates
|
CN104955952A
(zh)
|
2013-01-30 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
Lna寡核苷酸碳水化合物缀合物
|
WO2014130922A1
(en)
|
2013-02-25 |
2014-08-28 |
Trustees Of Boston University |
Compositions and methods for treating fungal infections
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
SI2970974T1
(sl)
|
2013-03-14 |
2017-12-29 |
Alnylam Pharmaceuticals, Inc. |
Komplementarna komponenta C5 sestavkov IRNA in postopki njene uporabe
|
WO2014152211A1
(en)
|
2013-03-14 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP2978446B1
(de)
|
2013-03-27 |
2020-03-04 |
The General Hospital Corporation |
Anti-cd33 antikörper zur behandlung von morbus alzheimer
|
US10022372B2
(en)
|
2013-04-19 |
2018-07-17 |
Thomas Jefferson University |
Caveolin-1 related methods for treating glioblastoma with temozolomide
|
US10590412B2
(en)
|
2013-04-19 |
2020-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation nucleic acids through nonsense mediated decay
|
CN113018307A
(zh)
|
2013-05-22 |
2021-06-25 |
阿尔尼拉姆医药品有限公司 |
SERPINA1 iRNA组合物及其使用方法
|
WO2014197938A1
(en)
|
2013-06-13 |
2014-12-18 |
Antisense Therapeutics Ltd |
Combination therapy
|
DK3013959T3
(da)
|
2013-06-27 |
2020-02-17 |
Roche Innovation Ct Copenhagen As |
Antisense-oligomerer og konjugater målrettet pcsk9
|
EP3971287A1
(de)
|
2013-07-11 |
2022-03-23 |
ModernaTX, Inc. |
Zusammensetzungen mit synthetischen polynukleotiden zur codierung von crispr-verwandten proteinen und synthetischen sgrnas und verfahren zur verwendung
|
PL3041854T3
(pl)
|
2013-08-08 |
2020-06-29 |
The Scripps Research Institute |
Sposób miejscowo specyficznego oznakowania enzymatycznego kwasów nukleinowych in vitro przez inkorporację niewystępujących naturalnie nukleotydów
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
EP3052626A1
(de)
|
2013-10-02 |
2016-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
PL3052628T3
(pl)
|
2013-10-04 |
2020-08-24 |
Alnylam Pharmaceuticals, Inc. |
Kompozycje i sposoby hamowania ekspresji genu ALAS1
|
KR102507624B1
(ko)
|
2013-11-22 |
2023-03-09 |
미나 테라퓨틱스 리미티드 |
C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법
|
CA2844640A1
(en)
|
2013-12-06 |
2015-06-06 |
The University Of British Columbia |
Method for treatment of castration-resistant prostate cancer
|
WO2015089368A2
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
AU2015214264B2
(en)
|
2014-02-04 |
2018-12-20 |
Curis, Inc. |
Mutant Smoothened and methods of using the same
|
JP6594902B2
(ja)
|
2014-02-11 |
2019-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ケトヘキソキナーゼ(KHK)iRNA組成物及びその使用方法
|
TWI638047B
(zh)
|
2014-04-09 |
2018-10-11 |
史基普研究協會 |
藉由核酸三磷酸酯轉運子將非天然或經修飾的核苷三磷酸酯輸入至細胞中
|
ES2932304T3
(es)
|
2014-04-17 |
2023-01-17 |
Biogen Ma Inc |
Composiciones y métodos para la modulación del empalme de SMN2 en un sujeto
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
WO2015175510A1
(en)
|
2014-05-12 |
2015-11-19 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating a serpinc1-associated disorder
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
MX2016015126A
(es)
|
2014-05-22 |
2017-02-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
|
EP3164113B1
(de)
|
2014-06-04 |
2019-03-27 |
Exicure, Inc. |
Multivalente freisetzung von immunmodulatoren durch liposomale sphärische nukleinsäuren für prophylaktische oder therapeutische anwendungen
|
HRP20220379T1
(hr)
|
2014-06-10 |
2022-05-27 |
Erasmus University Medical Center Rotterdam |
Antisense oligonukleotidi korisni u liječenju pompeove bolesti
|
WO2015200697A1
(en)
|
2014-06-25 |
2015-12-30 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
CA2955250A1
(en)
|
2014-07-16 |
2016-01-21 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
BR112017001860A2
(pt)
|
2014-07-31 |
2018-02-27 |
Uab Research Foundation |
peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal
|
CA2959386C
(en)
|
2014-08-29 |
2024-06-04 |
Lee Adam Wheeler |
Methods and compositions for the treatment of cancer
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
EP3198012B1
(de)
|
2014-09-26 |
2019-09-04 |
University of Massachusetts |
Rna-modulierende stoffe
|
WO2016061487A1
(en)
|
2014-10-17 |
2016-04-21 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
WO2016069694A2
(en)
|
2014-10-30 |
2016-05-06 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
EP3221451A1
(de)
|
2014-11-17 |
2017-09-27 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein-c3 (apoc3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2017537619A
(ja)
|
2014-11-21 |
2017-12-21 |
ノースウェスタン ユニバーシティ |
球状核酸ナノ粒子複合体の配列特異的細胞内取込
|
US9517270B2
(en)
|
2014-12-08 |
2016-12-13 |
The Board Of Regents Of The University Of Texas System |
Lipocationic polymers and uses thereof
|
EP3234141A4
(de)
|
2014-12-18 |
2018-06-20 |
Alnylam Pharmaceuticals, Inc. |
Reversir-tm-verbindungen
|
EP3247988A4
(de)
|
2015-01-23 |
2018-12-19 |
Vanderbilt University |
Robustes interferometer und verfahren zur verwendung davon
|
US10676726B2
(en)
|
2015-02-09 |
2020-06-09 |
Duke University |
Compositions and methods for epigenome editing
|
EP3256587A2
(de)
|
2015-02-13 |
2017-12-20 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing-3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016135559A2
(en)
|
2015-02-23 |
2016-09-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
US10961532B2
(en)
|
2015-04-07 |
2021-03-30 |
The General Hospital Corporation |
Methods for reactivating genes on the inactive X chromosome
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
AU2016287499B2
(en)
|
2015-06-29 |
2022-08-04 |
Caris Science, Inc. |
Therapeutic oligonucleotides
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
US11053495B2
(en)
|
2015-07-17 |
2021-07-06 |
Alnylam Pharmaceuticals, Inc. |
Multi-targeted single entity conjugates
|
CA2993652A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
JP7028764B2
(ja)
|
2015-09-02 |
2022-03-02 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
プログラム細胞死1リガンド1(PD-L1)iRNA組成物およびその使用方法
|
KR20240027890A
(ko)
|
2015-09-14 |
2024-03-04 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
지질양이온성 덴드리머 및 이의 용도
|
CA2998287A1
(en)
|
2015-09-24 |
2017-04-20 |
Crispr Therapeutics Ag |
Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
|
US11970710B2
(en)
|
2015-10-13 |
2024-04-30 |
Duke University |
Genome engineering with Type I CRISPR systems in eukaryotic cells
|
AU2016344609B2
(en)
|
2015-10-28 |
2022-05-12 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of duchenne muscular dystrophy
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
CA2999649A1
(en)
|
2015-11-06 |
2017-05-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of glycogen storage disease type 1a
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
EP3967758A1
(de)
|
2015-12-01 |
2022-03-16 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von alpha-1-antitrypsin-defizienz
|
CA3007152A1
(en)
|
2015-12-07 |
2017-06-15 |
Erasmus University Medical Center Rotterdam |
Enzymatic replacement therapy and antisense therapy for pompe disease
|
US11761007B2
(en)
|
2015-12-18 |
2023-09-19 |
The Scripps Research Institute |
Production of unnatural nucleotides using a CRISPR/Cas9 system
|
SG11201805320XA
(en)
|
2015-12-23 |
2018-07-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
|
US10627396B2
(en)
|
2016-01-29 |
2020-04-21 |
Vanderbilt University |
Free-solution response function interferometry
|
WO2017134529A1
(en)
|
2016-02-02 |
2017-08-10 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
WO2017141109A1
(en)
|
2016-02-18 |
2017-08-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
|
WO2017147087A1
(en)
|
2016-02-25 |
2017-08-31 |
The Brigham And Women's Hospital, Inc. |
Treatment methods for fibrosis targeting smoc2
|
AU2017235278C1
(en)
|
2016-03-14 |
2022-03-10 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for reduction of PD-L1 expression
|
WO2017158422A1
(en)
|
2016-03-16 |
2017-09-21 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hereditary haemochromatosis
|
US10731166B2
(en)
|
2016-03-18 |
2020-08-04 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
SG10202010261YA
(en)
|
2016-04-18 |
2020-11-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
WO2017191503A1
(en)
|
2016-05-05 |
2017-11-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
US10562849B2
(en)
|
2016-05-16 |
2020-02-18 |
The Board Of Regents Of The University Of Texas System |
Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids
|
CA3025486A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
WO2017214518A1
(en)
|
2016-06-10 |
2017-12-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
ES2929047T3
(es)
|
2016-06-24 |
2022-11-24 |
Scripps Research Inst |
Transportador de nucleósido trifosfato novedoso y usos del mismo
|
US11174469B2
(en)
|
2016-06-29 |
2021-11-16 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
|
US11564997B2
(en)
|
2016-06-29 |
2023-01-31 |
Crispr Therapeutics Ag |
Materials and methods for treatment of friedreich ataxia and other related disorders
|
US11427838B2
(en)
|
2016-06-29 |
2022-08-30 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
|
WO2018007976A1
(en)
|
2016-07-06 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of pain related disorders
|
CA3029141A1
(en)
|
2016-07-06 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of pain related disorders
|
WO2018007871A1
(en)
|
2016-07-08 |
2018-01-11 |
Crispr Therapeutics Ag |
Materials and methods for treatment of transthyretin amyloidosis
|
US11253601B2
(en)
|
2016-07-11 |
2022-02-22 |
Translate Bio Ma, Inc. |
Nucleic acid conjugates and uses thereof
|
WO2018020323A2
(en)
|
2016-07-25 |
2018-02-01 |
Crispr Therapeutics Ag |
Materials and methods for treatment of fatty acid disorders
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
NL2017295B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Antisense oligomeric compound for Pompe disease
|
EP3532638A4
(de)
|
2016-10-31 |
2020-07-29 |
University of Massachusetts |
Targeting von microrna-101-3p in der krebstherapie
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
JP7206214B2
(ja)
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル (ディービーエイ シアトル チルドレンズ リサーチ インスティテュート) |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
KR102619197B1
(ko)
|
2017-01-23 |
2024-01-03 |
리제너론 파마슈티칼스 인코포레이티드 |
Hsd17b13 변종 및 이것의 용도
|
US20200216857A1
(en)
|
2017-02-22 |
2020-07-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
|
EP3585895A1
(de)
|
2017-02-22 |
2020-01-01 |
CRISPR Therapeutics AG |
Zusammensetzungen und verfahren zur geneditierung
|
US11407997B2
(en)
|
2017-02-22 |
2022-08-09 |
Crispr Therapeutics Ag |
Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disorders
|
WO2018154418A1
(en)
|
2017-02-22 |
2018-08-30 |
Crispr Therapeutics Ag |
Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
|
US11559588B2
(en)
|
2017-02-22 |
2023-01-24 |
Crispr Therapeutics Ag |
Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders
|
KR20200015895A
(ko)
|
2017-04-18 |
2020-02-13 |
알닐람 파마슈티칼스 인코포레이티드 |
B형 간염 바이러스 (hbv)에 감염된 대상체의 치료 방법
|
US20200384115A1
(en)
|
2017-04-21 |
2020-12-10 |
The Broad Institute , Inc. |
Targeted delivery to beta cells
|
WO2018209270A1
(en)
|
2017-05-11 |
2018-11-15 |
Northwestern University |
Adoptive cell therapy using spherical nucleic acids (snas)
|
WO2019097305A2
(en)
|
2017-05-12 |
2019-05-23 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
SG11202000167SA
(en)
|
2017-07-11 |
2020-02-27 |
Synthorx Inc |
Incorporation of unnatural nucleotides and methods thereof
|
AU2018301477A1
(en)
|
2017-07-13 |
2020-02-27 |
Alnylam Pharmaceuticals Inc. |
Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
|
MA49770A
(fr)
|
2017-08-03 |
2021-05-26 |
Synthorx Inc |
Conjugués de cytokine destinés au traitement de maladies prolifératives et infectieuses
|
US11667952B2
(en)
|
2017-08-24 |
2023-06-06 |
Takara Bio Usa, Inc. |
Methods of producing nucleic acids using oligonucleotides modified by a stimulus
|
EP4219715A3
(de)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
|
CA3075205A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Stabilized hnf4a sarna compositions and methods of use
|
WO2019055460A1
(en)
|
2017-09-13 |
2019-03-21 |
The Children's Medical Center Corporation |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF TRANSPOSON-ASSOCIATED DISEASES
|
WO2019079527A1
(en)
|
2017-10-17 |
2019-04-25 |
Casebia Therapeutics Limited Liability Partnership |
COMPOSITIONS AND METHODS FOR GENETIC EDITION FOR HEMOPHILIA A
|
US20210180091A1
(en)
|
2017-10-26 |
2021-06-17 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of hemoglobinopathies
|
AU2018360697A1
(en)
|
2017-11-01 |
2020-05-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
MA50578A
(fr)
|
2017-11-09 |
2021-09-15 |
Vertex Pharma |
Systèmes crispr/cas pour le traitement de dmd
|
EP3714054A1
(de)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
|
MA50877A
(fr)
|
2017-11-21 |
2020-09-30 |
Bayer Healthcare Llc |
Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante
|
CA3084955A1
(en)
|
2017-12-05 |
2019-06-13 |
Vertex Pharmaceuticals Incorporated |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
US11578323B2
(en)
|
2017-12-14 |
2023-02-14 |
Bayer Healthcare Llc |
RNA-programmable endonuclease systems and their use in genome editing and other applications
|
BR112020012088A2
(pt)
|
2017-12-18 |
2020-11-17 |
Alnylam Pharmaceuticals, Inc. |
composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
|
WO2019123430A1
(en)
|
2017-12-21 |
2019-06-27 |
Casebia Therapeutics Llp |
Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
|
CA3084632A1
(en)
|
2017-12-21 |
2019-06-27 |
Crispr Therapeutics Ag |
Materials and methods for treatment of usher syndrome type 2a
|
EP3737762A1
(de)
|
2018-01-12 |
2020-11-18 |
CRISPR Therapeutics AG |
Zusammensetzungen und verfahren zur geneditierung von genen durch transferrin-targeting
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
EP3749768A1
(de)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
EP3749767A1
(de)
|
2018-02-05 |
2020-12-16 |
Vertex Pharmaceuticals Incorporated |
Materialien und verfahren zur behandlung von hämoglobinopathien
|
US20210130824A1
(en)
|
2018-02-16 |
2021-05-06 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing by targeting fibrinogen-alpha
|
AU2019224159A1
(en)
|
2018-02-26 |
2020-10-01 |
Synthorx, Inc. |
IL-15 conjugates and uses thereof
|
CN112424348A
(zh)
|
2018-03-19 |
2021-02-26 |
克里斯珀医疗股份公司 |
新颖的rna-可编程的内切核酸酶系统及其用途
|
CA3095545A1
(en)
|
2018-03-30 |
2019-10-03 |
Rheinische Friedrich-Wilhelms-Universitat Bonn |
Aptamers for targeted activaton of t cell-mediated immunity
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
EP3775211B1
(de)
|
2018-04-12 |
2023-04-05 |
MiNA Therapeutics Limited |
Sirt1-sarna kompositionen und methoden zu deren verwendung
|
WO2019204668A1
(en)
|
2018-04-18 |
2019-10-24 |
Casebia Therapeutics Limited Liability Partnership |
Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
|
SG11202007874XA
(en)
|
2018-04-27 |
2020-09-29 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Rapamycin resistant cells
|
KR20210018267A
(ko)
|
2018-05-07 |
2021-02-17 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달
|
TW202016304A
(zh)
|
2018-05-14 |
2020-05-01 |
美商阿尼拉製藥公司 |
血管收縮素原(AGT)iRNA組成物及其使用方法
|
MX2021001056A
(es)
|
2018-08-13 |
2021-04-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
|
TW202020157A
(zh)
|
2018-08-16 |
2020-06-01 |
美商艾爾妮蘭製藥公司 |
用於抑制lect2基因表現之組合物及方法
|
CA3110661A1
(en)
|
2018-08-29 |
2020-03-05 |
University Of Massachusetts |
Inhibition of protein kinases to treat friedreich ataxia
|
JP2022500003A
(ja)
|
2018-09-18 |
2022-01-04 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ケトヘキソキナーゼ(KHK)iRNA組成物およびその使用方法
|
JP7470107B2
(ja)
|
2018-09-28 |
2024-04-17 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
トランスサイレチン(TTR)iRNA組成物及びTTR関連眼疾患を治療又は予防するためのその使用方法
|
AU2019362000A1
(en)
|
2018-10-17 |
2021-05-20 |
Bayer Healthcare Llc |
Compositions and methods for delivering transgenes
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2020132521A1
(en)
|
2018-12-20 |
2020-06-25 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
LT3897672T
(lt)
|
2018-12-20 |
2023-11-10 |
Vir Biotechnology, Inc. |
Kombinuota hbv terapija
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
EP3923974A4
(de)
|
2019-02-06 |
2023-02-08 |
Synthorx, Inc. |
Il-2-konjugate und verfahren zur verwendung davon
|
MA54951A
(fr)
|
2019-02-15 |
2021-12-22 |
Bayer Healthcare Llc |
Édition de gène pour l'hémophilie a avec une expression de facteur viii améliorée
|
WO2020171889A1
(en)
|
2019-02-19 |
2020-08-27 |
University Of Rochester |
Blocking lipid accumulation or inflammation in thyroid eye disease
|
MA55297A
(fr)
|
2019-03-12 |
2022-01-19 |
Bayer Healthcare Llc |
Nouveaux systèmes d'endonucléase à arn programmable haute fidélité et leurs utilisations
|
WO2020208361A1
(en)
|
2019-04-12 |
2020-10-15 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
BR112021022806A2
(pt)
|
2019-05-13 |
2022-01-25 |
Vir Biotechnology Inc |
Método para tratar a infecção crônica por hbv, sirna, usos de um sirna, e de um sirna e peg-ifna e de um sirna, peg-ifna e um nrti, método, composição para uso ou uso e kit
|
WO2020236600A1
(en)
|
2019-05-17 |
2020-11-26 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
CN114207129A
(zh)
|
2019-06-14 |
2022-03-18 |
斯克利普斯研究所 |
用于在半合成生物体中复制、转录和翻译的试剂和方法
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
EP4007811A2
(de)
|
2019-08-01 |
2022-06-08 |
Alnylam Pharmaceuticals, Inc. |
Carboxypeptidase-b2(cpb2)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4013870A1
(de)
|
2019-08-13 |
2022-06-22 |
Alnylam Pharmaceuticals, Inc. |
Irna-wirkstoffzusammensetzungen der kleinen ribosomalen proteinuntereinheit 25 (rps25) und verfahren zu ihrer verwendung
|
KR20220047598A
(ko)
|
2019-08-15 |
2022-04-18 |
신톡스, 인크. |
Il-2 콘쥬게이트를 사용한 면역 종양학 병용 요법
|
JP2022545101A
(ja)
|
2019-08-19 |
2022-10-25 |
ミナ セラピューティクス リミテッド |
オリゴヌクレオチドコンジュゲート組成物および使用方法
|
JP2022544817A
(ja)
|
2019-08-23 |
2022-10-21 |
シンソークス, インコーポレイテッド |
Il-15コンジュゲートおよびその使用
|
EP4025694A1
(de)
|
2019-09-03 |
2022-07-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum hemmen der lect2-genexpression
|
WO2021050554A1
(en)
|
2019-09-10 |
2021-03-18 |
Synthorx, Inc. |
Il-2 conjugates and methods of use to treat autoimmune diseases
|
EP4038189A1
(de)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum ausschalten einer ugt1a1-genexpression
|
EP4045652A1
(de)
|
2019-10-18 |
2022-08-24 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen eines elements der solute-carrier-familie und verwendungsverfahren dafür
|
WO2021081026A1
(en)
|
2019-10-22 |
2021-04-29 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
EP4051796A1
(de)
|
2019-11-01 |
2022-09-07 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum unterdrücken der dnajb1-prkaca-fusionsgenexpression
|
AU2020376840A1
(en)
|
2019-11-01 |
2022-04-07 |
Alnylam Pharmaceuticals, Inc. |
Huntingtin (HTT) iRNA agent compositions and methods of use thereof
|
TW202131952A
(zh)
|
2019-11-04 |
2021-09-01 |
美商欣爍克斯公司 |
介白素10接合物及其用途
|
AU2020378414A1
(en)
|
2019-11-06 |
2022-05-26 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
EP4055165A1
(de)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr)-irna-zusammensetzungen und verfahren zur verwendung davon für die behandlung oder prävention ttr-assoziierter augenerkrankungen
|
KR20220115946A
(ko)
|
2019-11-13 |
2022-08-19 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐 (agt) 관련 장애를 치료하기 위한 방법 및 조성물
|
US20230056569A1
(en)
|
2019-11-22 |
2023-02-23 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
MX2022006433A
(es)
|
2019-12-13 |
2022-06-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72) y metodos de uso de los mismos.
|
WO2021126734A1
(en)
|
2019-12-16 |
2021-06-24 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
EP4077674A1
(de)
|
2019-12-18 |
2022-10-26 |
Alia Therapeutics S.R.L. |
Zusammensetzungen und verfahren zur behandlung von retinitis pigmentosa
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
IL295445A
(en)
|
2020-02-10 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Preparations and methods for silencing vegf-a expression
|
IL295496A
(en)
|
2020-02-18 |
2022-10-01 |
Alnylam Pharmaceuticals Inc |
Apolipoprotein c3 (apoc3) irna preparations and methods of using them
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
CN115461460A
(zh)
|
2020-03-06 |
2022-12-09 |
阿尔尼拉姆医药品有限公司 |
用于抑制转甲状腺素蛋白(ttr)的表达的组合物和方法
|
CN115485383A
(zh)
|
2020-03-06 |
2022-12-16 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
EP4127171A2
(de)
|
2020-03-30 |
2023-02-08 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der dnajc15-genexpression
|
BR112022020145A2
(pt)
|
2020-04-06 |
2023-01-03 |
Alnylam Pharmaceuticals Inc |
Composições e métodos para silenciamento da expressão de myoc
|
EP4133076A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
|
EP4133079A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der scn9a-expression
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
AU2021263554A1
(en)
|
2020-04-27 |
2022-12-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein E (APOE) iRNA agent compositions and methods of use thereof
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
EP4150089A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von retinosin 1 (rs1)
|
EP4150077A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von transmembrankanalähnlichem protein 1 (tmc1)
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
EP4153746A1
(de)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der marc1-genexpression
|
IL298406A
(en)
|
2020-05-22 |
2023-01-01 |
Wave Life Sciences Ltd |
Double-stranded oligonucleotide assemblies and related methods
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
EP4168546A1
(de)
|
2020-06-18 |
2023-04-26 |
Alnylam Pharmaceuticals, Inc. |
Xanthindehydrogenase (xdh)-irna-zusammensetzungen und verfahren zur verwendung davon
|
BR112022026316A2
(pt)
|
2020-06-24 |
2023-03-07 |
Vir Biotechnology Inc |
Anticorpos neutralizantes do vírus da hepatite b engenheirados e usos dos mesmos
|
WO2021263026A1
(en)
|
2020-06-25 |
2021-12-30 |
Synthorx, Inc. |
Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies
|
WO2022011214A1
(en)
|
2020-07-10 |
2022-01-13 |
Alnylam Pharmaceuticals, Inc. |
Circular sirnas
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
EP4222264A1
(de)
|
2020-09-30 |
2023-08-09 |
CRISPR Therapeutics AG |
Materialien und verfahren zur behandlung von amyotropher lateralsklerose
|
EP4225917A1
(de)
|
2020-10-05 |
2023-08-16 |
Alnylam Pharmaceuticals, Inc. |
G-protein-gekoppelter rezeptor-75 (gpr75)-irna-zusammensetzungen und verfahren zur verwendung davon
|
MX2023004029A
(es)
|
2020-10-09 |
2023-04-27 |
Synthorx Inc |
Terapia de combinacion de inmunoncologia con conjugados de il-2 y pembrolizumab.
|
EP4225375A1
(de)
|
2020-10-09 |
2023-08-16 |
Synthorx, Inc. |
Immunonkologische therapien mit il-2-konjugaten
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
Coagulation factor iRNA compositions (F5) and methods of using them
|
EP4259795A1
(de)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Gerinnungsfaktor x (f10)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2024501857A
(ja)
|
2020-12-31 |
2024-01-16 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
WO2022150260A1
(en)
|
2021-01-05 |
2022-07-14 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
IL304880A
(en)
|
2021-02-12 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Superoxide dismutase 1 (SOD1) IRNA compositions and methods of using them to treat or prevent superoxide dismutase 1- (SOD1-) associated neurodegenerative diseases
|
WO2022174102A1
(en)
|
2021-02-12 |
2022-08-18 |
Synthorx, Inc. |
Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
|
TW202245843A
(zh)
|
2021-02-12 |
2022-12-01 |
美商欣爍克斯公司 |
Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
IL305153A
(en)
|
2021-02-26 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Ketohexokinase (KHK) iRNA compositions and methods of using them
|
WO2022187435A1
(en)
|
2021-03-04 |
2022-09-09 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
|
WO2022192519A1
(en)
|
2021-03-12 |
2022-09-15 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
KR20230160872A
(ko)
|
2021-03-26 |
2023-11-24 |
미나 테라퓨틱스 리미티드 |
Tmem173 sarna 조성물 및 사용 방법
|
IL307239A
(en)
|
2021-03-29 |
2023-11-01 |
Alnylam Pharmaceuticals Inc |
Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
CA3214540A1
(en)
|
2021-04-22 |
2022-10-27 |
Pasi A. Janne |
Compositions and methods for treating cancer
|
JP2024517686A
(ja)
|
2021-04-26 |
2024-04-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
膜貫通プロテアーゼ、セリン6(TMPRSS6)iRNA組成物およびその使用方法
|
JP2024519293A
(ja)
|
2021-04-29 |
2024-05-10 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
シグナル伝達兼転写活性化因子6(STAT6)iRNA組成物およびその使用方法
|
JP2024522068A
(ja)
|
2021-05-18 |
2024-06-11 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
ナトリウム-グルコース共輸送体2(sglt2)irna組成物およびその使用方法
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
EP4347823A1
(de)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patin-ähnliche phospholipasedomäne mit 3 (pnpla3)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4346904A1
(de)
|
2021-06-03 |
2024-04-10 |
Synthorx, Inc. |
Kopf-hals-krebskombinationstherapie mit einem il-2-konjugat und cetuximab
|
BR112023025224A2
(pt)
|
2021-06-04 |
2024-02-27 |
Alnylam Pharmaceuticals Inc |
Quadro de leitura aberto 72 do cromossomo humano 9 (c9orf72) composições de agente de irna e métodos de uso dos mesmos
|
WO2022260939A2
(en)
|
2021-06-08 |
2022-12-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
EP4101928A1
(de)
|
2021-06-11 |
2022-12-14 |
Bayer AG |
Programmierbare typ-v-rna-endonukleasesysteme
|
AU2022290382A1
(en)
|
2021-06-11 |
2023-11-23 |
Bayer Aktiengesellschaft |
Type v rna programmable endonuclease systems
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
KR20240026203A
(ko)
|
2021-06-30 |
2024-02-27 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오텐시노겐(agt)-관련 장애를 치료하는 방법 및 조성물
|
EP4367237A2
(de)
|
2021-07-09 |
2024-05-15 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai-verbindungen zur zns-verabreichung
|
WO2023285431A1
(en)
|
2021-07-12 |
2023-01-19 |
Alia Therapeutics Srl |
Compositions and methods for allele specific treatment of retinitis pigmentosa
|
WO2023003805A1
(en)
|
2021-07-19 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
|
IL309897A
(en)
|
2021-07-21 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Target gene IRNA compositions associated with a metabolic disorder and methods of using them
|
AU2022316139A1
(en)
|
2021-07-23 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Beta-catenin (ctnnb1) irna compositions and methods of use thereof
|
WO2023009687A1
(en)
|
2021-07-29 |
2023-02-02 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
CN117795074A
(zh)
|
2021-08-03 |
2024-03-29 |
阿尔尼拉姆医药品有限公司 |
转甲状腺素蛋白(TTR)iRNA组合物和其使用方法
|
IL310295A
(en)
|
2021-08-04 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
iRNA compositions and methods for silencing angiotensinogen (AGT)
|
IL310407A
(en)
|
2021-08-13 |
2024-03-01 |
Alnylam Pharmaceuticals Inc |
Factor XII (F12) IRNA compositions and methods of using them
|
EP4144841A1
(de)
|
2021-09-07 |
2023-03-08 |
Bayer AG |
Neue programmierbare rna-endonuklease-systeme mit verbesserter pam-spezifität und deren verwendung
|
WO2023044370A2
(en)
|
2021-09-17 |
2023-03-23 |
Alnylam Pharmaceuticals, Inc. |
Irna compositions and methods for silencing complement component 3 (c3)
|
AU2022345881A1
(en)
|
2021-09-20 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
|
IL311864A
(en)
|
2021-10-15 |
2024-06-01 |
Alnylam Pharmaceuticals Inc |
IRNA compositions for extrahepatic administration and methods of using them
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
TW202334418A
(zh)
|
2021-10-29 |
2023-09-01 |
美商艾拉倫製藥股份有限公司 |
杭丁頓(HTT)iRNA劑組成物及其使用方法
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
WO2023122573A1
(en)
|
2021-12-20 |
2023-06-29 |
Synthorx, Inc. |
Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
|
WO2023118349A1
(en)
|
2021-12-21 |
2023-06-29 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2023118068A1
(en)
|
2021-12-23 |
2023-06-29 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2023122750A1
(en)
|
2021-12-23 |
2023-06-29 |
Synthorx, Inc. |
Cancer combination therapy with il-2 conjugates and cetuximab
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023194359A1
(en)
|
2022-04-04 |
2023-10-12 |
Alia Therapeutics Srl |
Compositions and methods for treatment of usher syndrome type 2a
|
WO2023220744A2
(en)
|
2022-05-13 |
2023-11-16 |
Alnylam Pharmaceuticals, Inc. |
Single-stranded loop oligonucleotides
|
WO2023237587A1
(en)
|
2022-06-10 |
2023-12-14 |
Bayer Aktiengesellschaft |
Novel small type v rna programmable endonuclease systems
|
WO2024006999A2
(en)
|
2022-06-30 |
2024-01-04 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
WO2024039776A2
(en)
|
2022-08-18 |
2024-02-22 |
Alnylam Pharmaceuticals, Inc. |
Universal non-targeting sirna compositions and methods of use thereof
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024056880A2
(en)
|
2022-09-16 |
2024-03-21 |
Alia Therapeutics Srl |
Enqp type ii cas proteins and applications thereof
|
WO2024073732A1
(en)
|
2022-09-30 |
2024-04-04 |
Alnylam Pharmaceuticals, Inc. |
Modified double-stranded rna agents
|
WO2024105162A1
(en)
|
2022-11-16 |
2024-05-23 |
Alia Therapeutics Srl |
Type ii cas proteins and applications thereof
|
WO2024129743A2
(en)
|
2022-12-13 |
2024-06-20 |
Bluerock Therapeutics Lp |
Engineered type v rna programmable endonucleases and their uses
|